For CC, in June 2020, the FDA approved pembrolizumab (KEYTRUDA, Merck Sharp Dohme) for first-line treatment of patients with unresectable or metastatic MSI-H or dMMR CRC, independent of PD-L1 immunohistochemisty [8]. This evidence concerns the gene CD274 and colorectal carcinoma.